Business Context and Reporting Period
This Form 8-K filing by Aclaris Therapeutics, Inc. reports on the results of the 2017 Annual Meeting of Stockholders held on June 15, 2017. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 26,098,493 shares outstanding, 23,238,312 shares (89%) were present or represented by proxy. Two proposals were submitted and approved:
- Proposal 1: Election of Directors. Three nominees were elected to serve until the 2020 annual meeting.
- Anand Mehra, M.D.: 18,619,807 votes for; 2,364,941 votes withheld.
- Andrew Powell: 20,725,325 votes for; 259,423 votes withheld.
- Stephen A. Tullman: 16,131,320 votes for; 4,853,428 votes withheld.
There were 2,253,564 broker non-votes.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Votes For: 23,238,312
- Votes Against: 0
- Abstained: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Confirmation that the three elected directors (Mehra, Powell, Tullman) have accepted their positions and will serve until the 2020 annual meeting.
- Verification of the high level of shareholder support for the auditor ratification (100% of votes cast were in favor).
- Review of the definitive proxy statement filed on April 21, 2017, for detailed biographies of the directors and further context on the proposals.